MedTrace Logo

Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)

NCT00367822 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-03-07

No results posted yet for this study

Summary

The objective of this trial is to compare an individually optimized dose of the lisuride TTS patch against placebo and against an individually optimized dose of oral ropinirole (active- and placebo-controlled design) in idiopathic and uremic RLS patients with regard to efficacy, safety, and quality of life.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Lisuride

DRUG

Ropinirole

DRUG

Placebo

Sponsors & Collaborators

  • Axxonis Pharma AG

    lead INDUSTRY

Principal Investigators

  • Heike Benes, MD · Somnibene GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367822 on ClinicalTrials.gov